| TheraSphere (yttrium 90 microspheres) / Boston Scientific |
2009-016475-29: Treatment of advanced hepatocellular carcinoma (HCC) with portal vein thrombosis by hepatic intra-arterial injection of microspheres loaded with Yttrium-90 (Thera-Sphere) |
|
|
| Ongoing | 3 | 50 | Europe | Suspension for injection, TheraSphere | AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | advanced hepatocellular carcinoma (HCC) with portal vein thrombosis | | | | |
| Recruiting | 3 | 90 | RoW | TheraSphere™ Yttrium-90 Glass Microspheres, conventional Transarterial Chemoembolization(cTACE) | Boston Scientific Corporation | Inoperable Hepatocellular Carcinoma | 06/25 | 10/26 | | |
2020-003925-42: Study on the effect of 2 immunotherapy drugs in combination with radioactive glass spheres on the survival in liver cancer |
|
|
| Not yet recruiting | 2 | 84 | Europe | Tremelimumab, Durvalumab, TheraSphere, Solution for infusion, Implant, TheraSphere | Clinics of Munich University LMU, Astra Zeneca, Boston Scientific | Patients with hepatocellular cancer, not amenable to curative surgical or ablation treatment., tumor of the liver which cannot be removed by surgery or other ablation techniques, Diseases [C] - Cancer [C04] | | | | |
2021-001575-16: Selective Internal Radiation Therapy and Capecitabine (chemotherapy) treatment for liver cancer Traitement par Radiothérapie Interne Sélective et Capecitabine (chimiothérapie) dans le cancer du foie |
|
|
| Not yet recruiting | 2 | 62 | Europe | CAPECITABINE ACCORD, THERASPHERE, Coated tablet, Radiopharmaceutical precursor, solution, CAPECITABINE ACCORD, THERASPHERE | Centre Régional de lutte contre le Cancer Eugène Marquis, Boston Scientific Corporation, Centre Régional de lutte contre le cancer Eugène Marquis | Patients having operable intrahepatic cholangiocarcinoma Patients présentant un cholangiocarcinome intra-hépatique résécable, Biliary tract cancer Cancer des voies biliaires, Diseases [C] - Cancer [C04] | | | | |
2021-001907-33: A clinical study to assess how safe and effective it is for subjects with hepatocellular carcinoma (HCC) to receive radiation therapy with TheraSphere alone versus receiving radiation therapy with TheraSphere followed by immunotherapy (durvalumab and tremelimumab treatment) Estudio clínico para evaluar la seguridad y la eficacia de los sujetos con carcinoma hepatocelular (CHC) que reciben radioterapia con TheraSphere sola frente a los que reciben radioterapia con TheraSphere seguida de inmunoterapia (tratamiento con durvalumab y tremelimumab). |
|
|
| Not yet recruiting | 2 | 150 | Europe | Durvalumab, Tremelimumab, MEDI4736, MEDI1123, Concentrate for solution for infusion | Biocompatibles UK Ltd, a wholly owned indirect subsidiary of Boston Scientific Corporation, Boston Scientific Corporation | hepatocellular carcinoma carcinoma hepatocelular, a cancer that starts in the liver un cáncer que comienza en el hígado, Diseases [C] - Cancer [C04] | | | | |
RESOLVE, NCT06166576: Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis |
|
|
| Recruiting | 2 | 30 | RoW | Ablative radioembolization | Seoul National University Hospital | Hepatocellular Carcinoma | 11/27 | 11/27 | | |
NCT05620771: Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk |
|
|
| Recruiting | 2 | 84 | US | Atezolizumab and Bevacizumab, Y90 + TKI | Northwestern University, National Cancer Institute (NCI) | Hepatocellular Carcinoma | 07/24 | 07/25 | | |
ArTisaN, NCT04362436: TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets |
|
|
| Recruiting | 2 | 24 | Europe | TheraSpheres Selective Internal Radiation Therapy (SIRT) | Imperial College London, Biocompatibles UK Ltd, a BT International group company | Neuroendocrine Tumors, Liver Metastases | 09/24 | 09/24 | | |
SIRTCI, NCT04659382: Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 52 | Europe | Atezolizumab, Therasphere, XELOX, Bevacizumab | Federation Francophone de Cancerologie Digestive | Metastatic Colorectal Cancer, pMMR, MSS, Immune Checkpoint Inhibitor, Internal Radiotherapy | 10/24 | 10/24 | | |
EMERALD-Y90, NCT06040099: A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE |
|
|
| Recruiting | 2 | 100 | US | Durvalumab, MEDI4736, IMFINZI, Bevacizumab, AVASTIN, ZIRABEV, Transarterial Radioembolization (TARE), TheraSphere | AstraZeneca | Hepatocellular Carcinoma (HCC) | 07/26 | 07/26 | | |
| Recruiting | 2 | 100 | Europe, US | TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy | Boston Scientific Corporation, Biocompatibles UK Ltd | Hepatocellular Carcinoma | 06/27 | 06/27 | | |
SOLID, NCT04124991: Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC |
|
|
| Completed | 1/2 | 24 | RoW | Durvalumab, Imfinzi®, Radioembolization, TheraSphere™ | Seoul National University Hospital | Hepatocellular Carcinoma | 07/22 | 07/22 | | |
NCT06432036: Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial |
|
|
| Not yet recruiting | 1/2 | 25 | US | Angiogram, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Radioembolization, intra-arterial brachytherapy, Single Photon Emission Computed Tomography, Medical Imaging, Single Photon Emission Computed Tomography, Single Photon Emission Tomography, Single-Photon Emission Computed, single-photon emission computed tomography, SPECT, SPECT imaging, SPECT SCAN, SPET, ST, tomography, emission computed, single photon, Tomography, Emission-Computed, Single-Photon, Survey Administration, Yttrium Y 90 Glass Microspheres, TheraSphere, Y-90 Therasphere | Jonsson Comprehensive Cancer Center, Boston Scientific Corporation | Stage I Renal Cell Cancer, Stage II Renal Cell Cancer | 06/26 | 06/27 | | |
NCT03812562: Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection |
|
|
| Terminated | 1 | 2 | US | Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Yttrium Y 90 Glass Microspheres, TheraSphere | Northwestern University, Bristol-Myers Squibb, National Cancer Institute (NCI) | Hepatocellular Carcinoma | 10/23 | 10/23 | | |
FRONTIER, NCT05303467: A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM |
|
|
| Recruiting | 1 | 12 | US | TheraSphere GBM, TheraSphere™ GBM Y-90 Glass Microspheres (TheraSphere GBM) | Boston Scientific Corporation | Glioblastoma Multiforme, Recurrent Glioblastoma | 12/24 | 06/25 | | |
NCT04518748: Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy. |
|
|
| Recruiting | 1 | 45 | US | Yttrium-90, Y-90, Selective Internal Radiation Therapy, SIRT, Stereotactic Body Radiation Therapy, SBRT, PET/CT, Therasphere | University of Michigan Rogel Cancer Center, Department of Health and Human Services, National Institute for Biomedical Imaging and Bioengineering (NIBIB) | Liver Malignancy | 05/28 | 11/28 | | |
NCT00589030: Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery |
|
|
| No Longer Available | N/A | | US | brachytherapy, yttrium Y 90 glass microspheres | City of Hope Medical Center | Liver Cancer | 09/14 | 09/14 | | |
NCT00701168: Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer |
|
|
| No Longer Available | N/A | | US | yttrium Y 90 microspheres (Therasphere®) | Leo W. Jenkins Cancer Center | Carcinoma, Hepatocellular, Neoplasm Metastasis | | | | |
NCT03686709: Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment |
|
|
| Recruiting | N/A | 20 | US | Post therapy PET/CT Imaging | University of Tennessee, Biocompatibles UK Ltd | Hepatocellular Carcinoma, Radiation Exposure | 06/19 | 12/19 | | |
NCT04517643: TheraSphere® For Treatment of Metastases in Liver |
|
|
| Completed | N/A | 4 | US | Therasphere Therapy | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Colorectal Cancer Metastatic, Colorectal Cancer | 09/21 | 12/22 | | |
NCT02960620: Therasphere for Unresectable Primary or Secondary Liver Neoplasia |
|
|
| No Longer Available | N/A | | US | TheraSphere Treatment | H. Lee Moffitt Cancer Center and Research Institute, Biocompatibles UK Ltd, BTG International Inc. | Liver Cancer, Liver Neoplasms, HepatoCellular Carcinoma | | | | |
NCT05233098: TheraSphere Post-Approval Study to Calculate the Radiation-absorbed Dose of Tc-99m MAA. |
|
|
| Completed | N/A | 5 | US | Technetium-99m macroaggregated albumin (Tc-99m MAA) | Boston Scientific Corporation | Hepatocellular Carcinoma | 06/23 | 06/23 | | |
PROACTIF, NCT04069468: Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC) |
|
|
| Active, not recruiting | N/A | 500 | Europe | TheraSphere, Yttrium-90 Glass Microspheres | Boston Scientific Corporation, Biocompatibles UK Ltd | Hepatocellular Carcinoma | 01/24 | 01/25 | | |
| Completed | N/A | 202 | RoW | Therasphere | Ankara University, Boston Scientific Corporation | Transarterial Radioembolization | 03/24 | 04/24 | | |
VOYAGER, NCT06192758: First In Human Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device |
|
|
| Suspended | N/A | 36 | US | TheraSphere PCa, TheraSphere PCa - Yttrium-90 Glass Microspheres | Boston Scientific Corporation | Prostate, Cancer | 11/27 | 08/32 | | |
NCT03896646: Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) |
|
|
| Active, not recruiting | N/A | 42 | US | Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, computerized tomography, CT, CT SCAN, tomography, Hepatobiliary Iminodiacetic Acid Scan, HIDA Scan, Single Photon Emission Computed Tomography, Medical Imaging, Single Photon Emission Computed Tomography, Single Photon Emission Tomography, single-photon emission computed tomography, SPECT, SPECT imaging, SPECT SCAN, SPET, tomography, emission computed, single photon, Tomography, Emission-Computed, Single-Photon, Yttrium Y 90 Glass Microspheres, TheraSphere, Yttrium-90 Microsphere Radioembolization, Yttrium Y 90 Microsphere Therapy, Yttrium-90 Radioembolization | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma | 09/24 | 09/24 | | |
NCT03059030: Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia |
|
|
| Active, not recruiting | N/A | 20 | US | TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc. | Northwestern University, BTG International Inc. | Thrombocytopenia, Cirrhosis | 04/25 | 04/25 | | |
REALM, NCT05953961: 90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia |
|
|
| Recruiting | N/A | 50 | US | Therasphere 90Y, Microwave Ablation | Ochsner Health System, Boston Scientific Corporation | Carcinoma, Hepatocellular | 08/26 | 01/27 | | |
